Abstract
The incidence of multiple myeloma in Canada is 55 per 1 000 000 people, and the prevalence is increasing.[1][1] Novel therapies, such as immunomodulatory drugs and proteasome inhibitors, have increased progression-free 5-year survival from 29% in 1997 to 68% in 2014 among patients who have received
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
